Indications
Doxorubicin Hydrochloride Liposome (PLD) injection is used to treat ovarian cancer in patients whose disease has progressed or recurred after platinum-based chemotherapy. It is also used for AIDS-related Kaposi's sarcoma, in patients whose disease has progressed on prior combination chemotherapy or who are intolerant to such therapy. In multiple myeloma, PLD is given in combination with Bortezomib to patients who have not previously received Bortezomib and have received at least one prior therapy. It is also indicated as monotherapy for patients with metastatic breast cancer who have an increased cardiac risk with conventional PLD.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from Streptomyces Peucetius var. Caesius. Doxorubicin Hydrochloride Liposome injection is Doxorubicin Hydrochloride encapsulated in Stealth Liposomes and given intravenously. More than 90 % of the drug is encapsulated in the Stealth Liposomes. The active ingredient of the injection is Doxorubicin Hydrochloride.
The mechanism of action of Doxorubicin Hydrochloride is thought to be related to its ability to bind DNA and inhibit nucleic acid synthesis. Cell structure studies have shown rapid cell penetration and perinuclear chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and induction of mutagenesis and chromosomal aberrations.
Doxorubicin Hydrochloride Liposome injection shows linear pharmacokinetics over the range of 10 to 20 mg/m2. After administration, disposition occurs in two phases. The first phase is relatively short (5 hours), and the second is prolonged (55 hours) and accounts for the majority of the area under the curve (AUC).
Distribution: Direct measurement shows that at least 90% of the drug remains Liposome-encapsulated while it circulates (the assay used cannot quantify less than 5 to 10% free doxorubicin).
Metabolism: Doxorubicinol, the major metabolite of Doxorubicin, was detected at concentrations of 0.8 to 26.2 ng/mL in the plasma of patients who received 10 or 20 mg/m2 Doxorubicin Hydrochloride Liposome injection.
Excretion: The plasma clearance of total Doxorubicin Hydrochloride Liposome injection was 0.041 L/h/m2 at a dose of 20 mg/m2. After administration of Doxorubicin Hydrochloride, the plasma clearance of doxorubicin is 24 to 35 L/h/m2.
Pregnancy & Breastfeeding
Pregnancy: Going by findings in animals and by how the medicine works, Doxorubicin Hydrochloride Liposome injection can harm the fetus when it is given to a pregnant woman. Avoid using it during the 1st trimester. Lactation: It isn't known whether the injection is present in human milk. Many drugs, including anthracyclines, are excreted in human milk, and the injection could cause serious adverse reactions in breastfed infants, so stop breastfeeding during treatment. Females and Males of Reproductive Potential: Pregnancy testing. Verify the pregnancy status of females of reproductive potential before starting the injection. Contraception: Doxorubicin Hydrochloride Liposome injection can cause fetal harm when given to a pregnant woman. It may also damage spermatozoa and testicular tissue, which could result in genetic fetal abnormalities. Infertility: In females of reproductive potential, the injection may cause infertility and amenorrhea. It may also result in oligospermia, azoospermia and permanent loss of fertility.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.
Side Effects & Interactions
Side Effects
No side-effect data recorded yet.